• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>China Distance Education Holdings Limited ADR

China Distance Education Holdings Limited ADR

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients ...

    New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes

  2. Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine

    Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine

  3. Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine

    Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine

  4. PEGASUS-TIMI 54 Study Shows That Long-Term Treatment with BRILINTA Reduced Thrombotic Cardiovascular Events in Patients with a History of Heart Attack

    PEGASUS-TIMI 54 Study Shows That Long-Term Treatment with BRILINTA Reduced Thrombotic Cardiovascular Events in Patients with a History of Heart Attack

  5. New Detailed Data From Phase 3 Study Show Amgen's Repatha™ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular ...

    New Detailed Data From Phase 3 Study Show Amgen's Repatha™ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.